{
  "1": {
    "premise": "78-year-old patient with stage IV HER2-positive breast cancer receiving daily paclitaxel at 315 mg/m² for 12 weeks, along with standard trastuzumab therapy (initial loading dose of 4 mg/kg followed by 2 mg/kg weekly for 12 weeks, then 6 mg/kg every 3 weeks for 40 weeks).",
    "statement": "This dosage of paclitaxel is appropriate for a 78-year-old patient and does not raise concern for neurotoxicity or myelosuppression.",
    "label": false,
    "responses": [
      "The premise describes a paclitaxel regimen of 315 mg/m² administered daily for 12 weeks in a 78-year-old woman. \n\nEstablished dosing:\n• Weekly paclitaxel for breast cancer is typically 80–100 mg/m² once weekly.\n• Every-3-week dosing is usually 175 mg/m² once every three weeks.\n\nA daily dose of 315 mg/m² is more than triple the standard single dose and would be given 7 times a week, leading to a cumulative weekly exposure >2 g/m²—orders of magnitude higher than recommended. Such excessive exposure carries a very high risk of severe peripheral neuropathy and profound myelosuppression, particularly in an elderly patient.\n\nHence, the statement claiming the dosage is appropriate and does not raise concern for neurotoxicity or myelosuppression is incorrect.\n\noutput: False",
      "The standard paclitaxel regimen for HER2-positive breast cancer is typically 80 mg/m² once weekly for 12 weeks or 175 mg/m² once every 3 weeks.  \nA dose of 315 mg/m² administered daily for 12 weeks is several-fold higher than accepted schedules and would carry a very high risk of peripheral neuropathy and severe myelosuppression, particularly in an elderly (78-year-old) patient.\n\nTherefore, the statement that this dosage is appropriate and does not raise concern for neurotoxicity or myelosuppression is incorrect.\n\noutput: False",
      "Paclitaxel is usually administered for metastatic breast cancer at 175 mg/m² intravenously every 3 weeks, or 80–90 mg/m² once weekly. Continuous daily administration is not a recognized regimen, and a dose of 315 mg/m² given every day for 12 weeks would far exceed accepted cumulative exposures. Such an excessive dose would be expected to produce severe myelosuppression (e.g., neutropenia) and significant peripheral neuropathy/neurotoxicity, especially in an elderly (78-year-old) patient whose marrow reserve and neurologic tolerance are lower than in younger adults. Therefore, the statement claiming the dosage is appropriate and non-toxic is incorrect.\n\noutput: False",
      "Paclitaxel is usually administered either 175 mg/m² every three weeks or about 80 mg/m² once weekly.  \nA dose of 315 mg/m² given every day for 12 weeks is far above accepted regimens and would be expected to produce severe toxicities, including peripheral neuropathy (neurotoxicity) and profound myelosuppression. Therefore, saying it is “appropriate” and “does not raise concern” is incorrect.\n\noutput: False",
      "The standard weekly paclitaxel dose for metastatic breast cancer is approximately 80–90 mg/m² once a week, or 175 mg/m² every three weeks.  \nA daily dose of 315 mg/m² for 12 consecutive weeks is far higher than recommended and would be expected to produce significant toxicity. Paclitaxel’s well-known dose-limiting adverse effects are peripheral neuropathy (neurotoxicity) and bone-marrow suppression (myelosuppression); these risks are even greater in an elderly (78-year-old) patient. Therefore, the statement that this dosage is appropriate and does not raise concern for neurotoxicity or myelosuppression is incorrect.\n\noutput: False",
      "Paclitaxel regimens for breast cancer are typically either 175 mg/m² every 3 weeks or 80–90 mg/m² once weekly for 12 weeks. A dose of 315 mg/m² given every day for 12 weeks far exceeds recommended dosing and would be expected to produce severe toxicities, notably peripheral neuropathy and marked myelosuppression. Therefore, saying that this dosage is appropriate and does not raise concern for neurotoxicity or myelosuppression is incorrect.\n\noutput: False",
      "Paclitaxel standard dosing for metastatic breast cancer is typically 175 mg/m² every 3 weeks or 80–90 mg/m² weekly. A daily dose of 315 mg/m² for 12 weeks is far above established regimens and would carry a very high risk of cumulative peripheral neuropathy and profound myelosuppression, especially in a 78-year-old. Therefore, the statement that this dose is appropriate and does not raise concern for neurotoxicity or myelosuppression is incorrect.  \noutput: False",
      "Paclitaxel dosing for breast cancer is typically 80–100 mg/m² weekly or 175–200 mg/m² every 3 weeks. A regimen of 315 mg/m² administered daily for 12 weeks far exceeds accepted dosing guidelines and would be expected to cause significant neurotoxicity and myelosuppression, particularly in an elderly (78-year-old) patient. Therefore, the statement that this dosage is appropriate and does not raise concern for toxicity is incorrect.\n\noutput: False",
      "Paclitaxel is normally administered as:\n• 175 mg/m² IV every 3 weeks, or\n• 80–90 mg/m² IV weekly.\n\nA daily dose of 315 mg/m² for 12 weeks is far above standard practice and would carry a very high risk of the drug’s known dose-limiting toxicities, especially peripheral neuropathy (neurotoxicity) and significant myelosuppression. Therefore the statement that this dosage is appropriate and does not raise such concerns is incorrect.\n\noutput: False",
      "Paclitaxel standard doses in metastatic HER2-positive breast cancer are usually:\n• 80–90 mg/m² given weekly, or\n• 175–220 mg/m² given every three weeks.\n\nA daily dose of 315 mg/m² for 12 consecutive weeks is far higher than any accepted regimen and would almost certainly produce severe toxicities. Paclitaxel’s well-known dose-limiting toxicities include peripheral neuropathy (neurotoxicity) and profound myelosuppression (particularly neutropenia). In an elderly patient (78 years old), these risks are even greater.\n\nTherefore, saying that this dosage “is appropriate … and does not raise concern for neurotoxicity or myelosuppression” is factually incorrect.\n\noutput: False"
    ]
  },
  "2": {
    "premise": "65-year-old male with non-Hodgkin lymphoma receiving cyclophosphamide at 415mg/m² intravenously on Days 1–5 of each 21-day cycle, for 4 cycles.",
    "statement": "This cyclophosphamide regimen is considered tolerable and does not present excessive hematologic risk for older patients.",
    "label": false,
    "responses": [
      "The regimen described (cyclophosphamide 415 mg/m² IV daily for 5 consecutive days every 21 days, total ≈2 g/m² per cycle) delivers a cumulative dose several-fold higher than the single-day 750 mg/m² used in standard CHOP. Five-day schedules of cyclophosphamide are well known to cause pronounced myelosuppression, with high rates of grade 3-4 neutropenia, thrombocytopenia, and infection. Older patients (≥ 60 years) in particular have reduced marrow reserve and experience greater hematologic toxicity. Therefore, the claim that this regimen is “tolerable and does not present excessive hematologic risk for older patients” is not supported. \n\noutput: False",
      "Cyclophosphamide is well known to cause dose-dependent myelosuppression.  \nStandard lymphoma regimens for adults (e.g., CHOP or CVP) typically give 750 mg/m² on Day 1 every 21 days (≈750 mg/m² total per cycle).  \nThe regimen in the premise delivers 415 mg/m² daily for 5 consecutive days (≈2 070 mg/m² per cycle), nearly three times the cumulative dose of standard therapy.  \n\nIn patients ≥65 years old, the risk of grade 3–4 neutropenia, thrombocytopenia, and infection rises markedly with higher cumulative doses. Such a schedule generally requires close blood-count monitoring, prophylactic growth-factor support, and may still necessitate dose reductions or delays. Therefore, it cannot be characterized as “tolerable” without excessive hematologic risk for older patients.\n\noutput: False",
      "Cyclophosphamide 415 mg/m² intravenously for 5 consecutive days (total ≈2 g/m² per cycle) is a relatively intensive dosing schedule. Such multi-day, high-cumulative doses are well known to cause pronounced bone-marrow suppression (grade 3–4 neutropenia, thrombocytopenia, anemia) and carry substantial infection and transfusion risks, risks that increase with patient age. In contrast, regimens regarded as “tolerable” for older non-Hodgkin lymphoma patients (e.g., CHOP) typically give cyclophosphamide 750 mg/m² only on day 1 of a 21-day cycle. Therefore, saying that this regimen “does not present excessive hematologic risk for older patients” is not supported by clinical evidence. \n\noutput: False",
      "Cyclophosphamide’s principal dose-limiting toxicity is myelosuppression, with neutropenia and thrombocytopenia more frequent and more severe in patients over 60 years of age.  \nA schedule of 415 mg/m² intravenously each day for 5 consecutive days (≈2 g/m² per cycle) is a high cumulative dose compared with the standard single-day 750 mg/m² used in CHOP. Such multi-day high-dose schedules have a well-documented risk of significant hematologic toxicity, often requiring growth-factor support and close monitoring. Therefore, the regimen cannot be described as routinely “tolerable” or free of “excessive hematologic risk” in a 65-year-old patient.\n\noutput: False",
      "Cyclophosphamide 415 mg/m² administered intravenously on five consecutive days (total ≈2 g/m² per 21-day cycle) is a markedly myelosuppressive schedule. In patients ≥65 years, such dosing is associated with a high incidence of grade 3–4 neutropenia, thrombocytopenia, and the attendant infection/bleeding risks. Standard lymphoma regimens for older adults (e.g., CHOP) give a single day 750 mg/m² dose per cycle, precisely to limit hematologic toxicity. Therefore, saying that this five-day regimen “does not present excessive hematologic risk for older patients” is not supported by clinical experience or established guidelines.\n\noutput: False",
      "Cyclophosphamide 415 mg/m² daily for 5 consecutive days (total ≈ 2 g/m² per cycle) is a high-dose schedule well known to cause profound, and sometimes prolonged, neutropenia and thrombocytopenia. Older patients, such as the 65-year-old in the premise, are at even greater risk of severe hematologic toxicity. Therefore, it is inaccurate to say this regimen “does not present excessive hematologic risk” and is simply “tolerable” for older patients. \n\noutput: False",
      "Cyclophosphamide is a strongly myelosuppressive alkylating agent, and cumulative doses in the 2 g/m² range per 21-day cycle (415 mg/m² daily × 5 = ~2.1 g/m²) are well known to carry a high risk of grade 3–4 neutropenia, leukopenia, and thrombocytopenia. Older patients (>60 years) have reduced bone-marrow reserve and are more susceptible to prolonged cytopenias and infectious complications. Standard regimens used in older non-Hodgkin lymphoma patients (e.g., CHOP) typically give a single dose of 750 mg/m² on Day 1 rather than five consecutive daily doses, precisely to limit hematologic toxicity. Therefore, the described 5-day schedule would generally be considered more hematotoxic and not “tolerable” without heightened supportive care.  \n\noutput: False",
      "Cyclophosphamide causes dose-dependent myelosuppression. Giving 415 mg/m² IV daily for 5 consecutive days (≈2 g/m² per cycle) is an intensive schedule similar to regimens known to produce prolonged neutropenia and thrombocytopenia. In patients ≥65 years, marrow reserve is reduced and infection/bleeding complications are significantly more common; such protocols are considered hematologically high-risk and are often modified or avoided in older adults. Therefore, the claim that this regimen “does not present excessive hematologic risk for older patients” is incorrect.  \noutput: False",
      "The described dosing schedule delivers approximately 2 g/m² of cyclophosphamide per cycle, a cumulative amount well above the single-day doses (e.g., 750 mg/m² on Day 1) commonly used in standard CHOP-like regimens. Multi-day, high-total-dose cyclophosphamide is well known to carry substantial myelosuppressive effects, and patients ≥65 years are at increased risk for severe neutropenia, anemia, thrombocytopenia, and related complications. Therefore, asserting that this regimen “does not present excessive hematologic risk for older patients” is not supported by clinical experience or evidence.\n\noutput: False",
      "Cyclophosphamide’s principal dose-limiting toxicity is myelosuppression.  \nA regimen of 415 mg/m² IV daily for 5 consecutive days (≈2 g/m² per cycle) is toward the higher end of conventional dosing; in patients ≥65 years, this intensity is well-documented to cause a high incidence of grade 3/4 neutropenia and thrombocytopenia unless growth-factor support is used. Therefore, it cannot be characterized as having no excessive hematologic risk for older patients.\n\noutput: False"
    ]
  },
  "3": {
    "premise": "68-year-old female with type 2 diabetes and chronic kidney disease (eGFR 25 mL/min/1.73m²) receiving metformin 1000mg twice daily.",
    "statement": "This dosage of metformin is acceptable even in patients with severe renal impairment and does not increase the risk of lactic acidosis.",
    "label": false,
    "responses": [
      "Metformin is primarily renally excreted. In patients with an eGFR < 30 mL/min/1.73 m² (severe renal impairment), current guidelines recommend discontinuing metformin because its accumulation markedly increases the risk of metformin-associated lactic acidosis. A dosage of 1000 mg twice daily (2000 mg/day) is therefore contraindicated in the scenario described. Hence, the statement claiming this dosage is acceptable and does not raise lactic acidosis risk is incorrect.\n\noutput: False",
      "output: False",
      "output: False",
      "Current guidelines advise discontinuing metformin when eGFR is below 30 mL/min/1.73 m², because the drug’s accumulation in severe renal impairment markedly raises the risk of metformin-associated lactic acidosis. A dose of 1000 mg twice daily (2000 mg/day) is therefore not acceptable for a patient whose eGFR is 25 mL/min/1.73 m², and it does increase the risk of lactic acidosis.\n\noutput: False",
      "Metformin is generally contraindicated in patients with an eGFR below 30 mL/min/1.73 m² because accumulation of the drug increases the risk of metformin-associated lactic acidosis. A dose of 1000 mg twice daily (2000 mg/day) is therefore not considered acceptable in a patient with severe renal impairment (eGFR 25 mL/min/1.73 m²) and does carry a higher risk of lactic acidosis.\n\noutput: False",
      "Metformin is generally contraindicated in patients whose estimated glomerular filtration rate (eGFR) is below 30 mL/min/1.73 m² because accumulation of the drug can increase the risk of metformin-associated lactic acidosis. In an individual with an eGFR of 25 mL/min/1.73 m², a dose of 1000 mg twice daily (2000 mg/day) exceeds recommended limits and is not considered safe. Therefore, the assertion that this dosage is acceptable and does not raise the risk of lactic acidosis is incorrect.\n\noutput: False",
      "Metformin use is generally contraindicated or should be discontinued when eGFR is below 30 mL/min/1.73 m² because the risk of metformin-associated lactic acidosis rises markedly. A dose of 1000 mg twice daily (2 g/day) is not considered acceptable in severe renal impairment (eGFR 25 mL/min/1.73 m²). Therefore, the statement is incorrect.  \n\noutput: False",
      "Metformin is primarily eliminated by the kidneys. Regulatory guidance (e.g., FDA, EMA, ADA/KDIGO) states that metformin is contraindicated when eGFR is below 30 mL/min/1.73 m² because of the markedly increased risk of metformin accumulation and lactic acidosis. In patients with eGFR 30–45 mL/min/1.73 m², the maximum recommended daily dose is usually 500 mg–1000 mg and initiation is discouraged. An eGFR of 25 mL/min/1.73 m² therefore represents severe renal impairment in which any dose of metformin, let alone 1000 mg twice daily, is not considered acceptable and does increase the risk of lactic acidosis. Accordingly, the statement is factually incorrect.\n\noutput: False",
      "output: False",
      "Metformin is primarily renally excreted. With an eGFR below 30 mL/min/1.73 m², current guidelines consider metformin contraindicated because reduced clearance markedly increases the risk of metformin-associated lactic acidosis. A dose of 1000 mg twice daily (2000 mg/day) is well above the recommended limit even for moderate renal impairment (eGFR 30-45 mL/min/1.73 m²). Therefore, such dosing is not acceptable in severe renal impairment and does increase the risk of lactic acidosis.\n\noutput: False"
    ]
  },
  "4": {
    "premise": "45‑year‑old patient with squamous cell carcinoma receiving weekly cetuximab at 250mg/m² and cisplatin at 250mg/m² daily for 7 days.",
    "statement": "This dosage of cisplatin is acceptable and does not exceed safe cumulative limits for toxicity.",
    "label": false,
    "responses": [
      "Cisplatin is commonly administered as 50–100 mg/m² once every 3–4 weeks, or 20–30 mg/m²/day for 5 days; cumulative nephrotoxicity and neurotoxicity become a major concern once total exposure approaches 400–500 mg/m².  \nThe regimen in the premise gives 250 mg/m² per day × 7 days = 1 750 mg/m² in one cycle, which is several-fold higher than accepted cumulative safety thresholds and would be expected to cause severe, potentially life-threatening toxicity.  \n\noutput: False",
      "Cisplatin is usually given at:\n\n• 50–100 mg/m² as a single dose every 3–4 weeks, or  \n• 20 mg/m² per day for 5 days every 3–4 weeks.\n\nToxicities (nephrotoxicity, neurotoxicity, ototoxicity) markedly increase when the cumulative lifetime dose exceeds roughly 400–600 mg/m².\n\nIn the premise the patient is receiving 250 mg/m² per day for 7 days, a total of 1 750 mg/m² in one cycle—more than three times the lifetime cumulative threshold and vastly beyond accepted single-cycle doses. This regimen would be expected to cause severe, unacceptable toxicity.\n\noutput: False",
      "Standard cisplatin dosing in solid-tumor protocols is typically  \n• 50–100 mg/m² every 3–4 weeks, or  \n• 20–40 mg/m² once weekly.  \n\nCumulative nephro- and oto-toxicity become a major concern when the lifetime total exceeds roughly 400 mg/m².\n\nThe regimen in the premise (250 mg/m² every day for 7 days) gives a single-cycle exposure of 1 750 mg/m²—more than four times the lifetime cumulative threshold and far above any accepted single-cycle or cumulative dose. Such a dose would be expected to produce profound, life-threatening toxicity.\n\nTherefore, the statement is incorrect.  \noutput: False",
      "Standard cisplatin regimens use 50-100 mg/m² once every 3–4 weeks (or 20-40 mg/m² on days 1–5 every 3–4 weeks). Lifetime cumulative doses above roughly 400–500 mg/m² markedly increase risk of irreversible nephro- and neuro-toxicity.  \nThe premise describes 250 mg/m² of cisplatin given daily for 7 days, i.e., 1 750 mg/m² in one week—many times higher than established safe limits. Therefore the dosage is not acceptable and far exceeds known toxicity thresholds.\n\noutput: False",
      "Cisplatin is ordinarily given at 50–100 mg/m² once every 3–4 weeks, or 20 mg/m² per day for 5 days (total 100 mg/m²) per cycle; cumulative lifetime doses above ≈400–500 mg/m² markedly increase the risk of severe nephro-, neuro- and ototoxicity.  \nThe regimen described—250 mg/m² every day for 7 days (total 1 750 mg/m² in a week)—is vastly higher than accepted dosing and would exceed safe cumulative limits by a wide margin.\n\noutput: False",
      "Standard cisplatin regimens typically administer 50–100 mg/m² once every 3–4 weeks, or 20 mg/m²/day for 5 days (total 100 mg/m² per cycle). Neuro-, oto- and nephro-toxicity rise steeply when the cumulative lifetime exposure exceeds about 400–500 mg/m².  \n\nIn the premise the patient is receiving 250 mg/m² daily for 7 days, a cumulative 1 750 mg/m² in one week—over three times the generally accepted lifetime upper limit. This far exceeds safe cumulative limits and would carry extreme toxicity risk.\n\noutput: False",
      "Standard cisplatin regimens are usually 50–100 mg/m² every 3–4 weeks, 20 mg/m² daily for 5 days, or 30–40 mg/m² weekly. Serious cumulative toxicities (nephrotoxicity, ototoxicity, neuropathy) are known to rise sharply once total lifetime exposure approaches 400–500 mg/m².  \nThe regimen in the premise—250 mg/m² every day for 7 days (total 1 750 mg/m² in a single week)—vastly exceeds any accepted single-cycle or cumulative exposure threshold and would be expected to cause profound, likely lethal toxicity.  \n\noutput: False",
      "Standard cisplatin regimens generally involve 50–100 mg/m² once every 3–4 weeks, or 20 mg/m² daily for 5 days (total ≈100 mg/m²) per cycle. Neuro- and nephro-toxicity markedly increase when cumulative lifetime exposure approaches 400–500 mg/m², and many protocols cap the cumulative dose at ≈800 mg/m².\n\nThe regimen described in the premise—250 mg/m² per day for 7 days (total 1 750 mg/m² in one week)—far exceeds accepted per-cycle and lifetime cumulative limits and would carry an unacceptable risk of severe toxicity.\n\noutput: False",
      "Cisplatin’s usual dosing regimens for solid tumors are 50-100 mg/m² on day 1 every 3-4 weeks or 20 mg/m² per day for 5 days every 3-4 weeks. Serious cumulative toxicities (notably nephrotoxicity, neurotoxicity, ototoxicity) generally limit lifetime exposure to roughly 400-500 mg/m². A regimen of 250 mg/m² DAILY for 7 days would deliver 1,750 mg/m² in a single week—more than three times the lifetime cumulative threshold and far above accepted single-dose limits. Therefore, this dosage is not acceptable and exceeds safe cumulative limits.\n\noutput: False",
      "Cisplatin is usually administered at 50–100 mg/m² once every 3–4 weeks (or 30–40 mg/m² weekly). Lifetime cumulative doses above roughly 400–500 mg/m² are associated with high risks of nephrotoxicity, ototoxicity, and neurotoxicity.  \nThe regimen described—250 mg/m² of cisplatin daily for 7 days—totals 1 750 mg/m² in just one week, several-fold higher than accepted cumulative safety limits. Therefore, the stated dosage is not acceptable and far exceeds safe limits.\n\noutput: False"
    ]
  },
  "5": {
    "premise": "72-year-old patient with advanced non-small cell lung cancer receiving cisplatin at 120mg/m² on Day 1 and vinorelbine 30mg/m² on Days 1 and 8 of a 21-day cycle, repeated for 6 cycles.",
    "statement": "This regimen is safe for elderly patients and does not raise particular concern for nephrotoxicity or hematologic toxicity.",
    "label": false,
    "responses": [
      "Cisplatin is well-known for dose-dependent nephrotoxicity, and advanced age increases that risk.  \nBoth cisplatin and vinorelbine commonly cause significant myelosuppression (e.g., neutropenia, anemia, thrombocytopenia).  \nTherefore, the regimen described cannot be characterized as free of particular concern for nephrotoxicity or hematologic toxicity in an elderly patient.\n\noutput: False",
      "The regimen of cisplatin 120 mg/m² (Day 1) plus vinorelbine 30 mg/m² (Days 1 & 8) is well-known to carry significant risks of nephrotoxicity from cisplatin and marked hematologic toxicity (especially neutropenia) from both agents. These toxicities are of even greater concern in elderly patients such as the 72-year-old described. Therefore, the statement claiming it is safe for elderly patients and does not raise concerns for nephrotoxicity or hematologic toxicity is incorrect. \n\noutput: False",
      "Cisplatin is well-known for dose-dependent nephrotoxicity, and elderly patients are at higher risk because of age-related decline in renal function and reduced physiologic reserve.  \nBoth cisplatin and vinorelbine can cause significant myelosuppression (neutropenia, anemia, thrombocytopenia). In fact, neutropenia is one of the dose-limiting toxicities of vinorelbine, and cisplatin frequently potentiates bone-marrow suppression.  \nTherefore, the described regimen does raise concerns for both kidney injury and hematologic toxicity, particularly in a 72-year-old patient.\n\noutput: False",
      "Cisplatin at doses ≥100 mg/m² is well known for causing dose-related nephrotoxicity, and the risk is higher in older adults whose baseline renal reserve is often reduced. It can also contribute to significant myelosuppression.  \nVinorelbine frequently causes neutropenia and other hematologic toxicities.  \nIn a 72-year-old patient, the combination of high-dose cisplatin (120 mg/m²) plus vinorelbine clearly raises concern for both nephrotoxicity and hematologic toxicity; special monitoring and possible dose adjustments are standard recommendations for this age group.  \n\nThe statement that the regimen is safe for elderly patients and “does not raise particular concern” for these toxicities is therefore incorrect.\n\noutput: False",
      "Cisplatin is well known for dose-related nephrotoxicity and for significant myelosuppression.  \nVinorelbine also commonly causes neutropenia and other hematologic toxicities.  \nBoth toxicities are of particular concern in elderly patients, and special monitoring or dose adjustment is often required.  \nTherefore, the statement that this regimen “does not raise particular concern for nephrotoxicity or hematologic toxicity” in an elderly patient is inaccurate.\n\noutput: False",
      "Cisplatin at 120 mg/m² is a relatively high dose, and cisplatin is well known for dose-related nephrotoxicity, with elderly patients at particular risk because of age-related decline in renal function. Vinorelbine commonly causes significant myelosuppression, especially neutropenia, which is a major hematologic toxicity. Therefore, this regimen in a 72-year-old patient does raise concern for both nephrotoxicity and hematologic toxicity and cannot be described as uniformly “safe” in this population.\n\noutput: False",
      "Cisplatin is well-known for dose-dependent nephrotoxicity, and both cisplatin and vinorelbine commonly cause significant myelosuppression. These risks are heightened in elderly patients such as the 72-year-old described. Therefore, the statement claiming the regimen is safe for elderly patients and does not raise concern for nephrotoxicity or hematologic toxicity is incorrect.  \n\noutput: False",
      "Cisplatin is well-known to cause dose-dependent nephrotoxicity, and vinorelbine frequently causes significant myelosuppression (neutropenia, anemia, thrombocytopenia). Elderly patients are at higher risk for both renal impairment from cisplatin and hematologic toxicity from vinorelbine. Therefore the statement that this regimen “does not raise particular concern for nephrotoxicity or hematologic toxicity” is incorrect.\n\noutput: False",
      "Cisplatin at 120 mg/m² is a high dose well known to cause dose-dependent nephrotoxicity as well as significant myelosuppression.  \nVinorelbine commonly produces neutropenia and other hematologic toxicities.  \nElderly patients, especially those over 70 years, are at increased risk for both renal impairment and bone-marrow suppression when treated with these agents.  \nTherefore, the regimen does raise particular concern for nephrotoxicity and hematologic toxicity and cannot be described as definitively “safe” in this population.\n\noutput: False",
      "Cisplatin at 120 mg/m² carries a well-known risk of nephrotoxicity, and both cisplatin and vinorelbine are associated with significant myelosuppression. These toxicities are of particular concern in elderly patients. Therefore, the statement is not correct.  \noutput: False"
    ]
  },
  "6": {
    "premise": "53-year-old female with triple-negative breast cancer receiving doxorubicin 90mg/m² every week for 8 weeks.",
    "statement": "This doxorubicin regimen is within acceptable cumulative dose limits and is not considered cardiotoxic.",
    "label": false,
    "responses": [
      "Doxorubicin’s generally accepted cumulative lifetime dose limit is about 450–550 mg/m² because cardiotoxicity rises steeply above this range.  \nThe regimen in the premise delivers 90 mg/m² × 8 weeks = 720 mg/m², which exceeds these limits and carries a high risk of cardiotoxicity.  \n\noutput: False",
      "The typical lifetime cumulative dose limit for doxorubicin is approximately 450–550 mg/m² because the risk of irreversible cardiomyopathy rises sharply beyond this range.  \nA regimen of 90 mg/m² weekly for 8 weeks results in a cumulative dose of 720 mg/m², which exceeds these accepted limits and carries a high risk of cardiotoxicity.  \nTherefore, the statement is incorrect.\n\noutput: False",
      "The cumulative dose of doxorubicin in the regimen described is:\n\n90 mg/m²/week × 8 weeks = 720 mg/m².\n\nEstablished cardiotoxicity data show that the recommended lifetime cumulative limit for doxorubicin is approximately 450–550 mg/m²; exceeding this markedly increases the risk of irreversible cardiomyopathy. A total dose of 720 mg/m² is well above these limits and is considered cardiotoxic.\n\nTherefore, the statement that the regimen is within acceptable limits and “is not considered cardiotoxic” is incorrect.\n\noutput: False",
      "The planned regimen results in a cumulative dose of 90 mg/m² × 8 = 720 mg/m². Standard guidelines cite a lifetime cumulative limit of approximately 450–550 mg/m² beyond which the risk of doxorubicin-induced cardiomyopathy rises sharply. Therefore, 720 mg/m² exceeds acceptable limits and is considered cardiotoxic.  \noutput: False",
      "Doxorubicin at 90 mg/m² given weekly for 8 weeks produces a cumulative dose of 720 mg/m² (90 mg/m² × 8). The generally accepted lifetime cumulative dose limit for doxorubicin is approximately 450–550 mg/m², beyond which the risk of cardiotoxicity rises substantially. Therefore, this regimen exceeds the accepted limit and is considered cardiotoxic.\n\noutput: False",
      "output: False",
      "The commonly accepted lifetime cumulative dose limit for doxorubicin is approximately 450–550 mg/m² because doses beyond this range markedly increase the risk of irreversible cardiomyopathy.  \nIn the premise, the patient is receiving 90 mg/m² each week for 8 weeks:\n\n90 mg/m² × 8 = 720 mg/m²\n\nA cumulative exposure of 720 mg/m² clearly exceeds the accepted safety threshold and is therefore considered highly cardiotoxic. Hence, the statement claiming the regimen is “within acceptable cumulative dose limits and is not considered cardiotoxic” is incorrect.\n\noutput: False",
      "The standard lifetime cumulative dose limit for conventional doxorubicin is generally 450–550 mg/m² because of its dose-related risk of irreversible cardiomyopathy.  \nA regimen of 90 mg/m² weekly for 8 weeks results in a cumulative exposure of 720 mg/m² (90 mg/m² × 8), which exceeds these accepted limits and is therefore considered cardiotoxic.  \n\noutput: False",
      "output: False",
      "The premise describes a regimen totaling 720 mg/m² of doxorubicin (90 mg/m² × 8 weeks). Established guidelines set the lifetime cumulative dose limit for doxorubicin at approximately 450–550 mg/m² to minimize the risk of irreversible cardiotoxicity. A total of 720 mg/m² exceeds this limit and is therefore regarded as cardiotoxic.\n\noutput: False"
    ]
  },
  "7": {
    "premise": "2-month-old infant diagnosed with metastatic melanoma receiving pembrolizumab 200mg intravenously every 3 weeks.",
    "statement": "This dosage of pembrolizumab is appropriate for infants and does not pose safety concerns despite limited study.",
    "label": false,
    "responses": [
      "Pembrolizumab is approved and well-studied only in adults and in children ≥ 6 months (at weight-based dosing of 2 mg/kg every 3 weeks or 200 mg in ≥40 kg adolescents). A fixed adult dose of 200 mg in a 2-month-old infant (~5–6 kg) would correspond to ~35–40 mg/kg—an exposure many times higher than recommended pediatric dosing, with unknown safety or efficacy. Current guidelines state that safety and dosing have not been established for infants this young. Therefore, claiming that this dosage is “appropriate” and poses no safety concerns is incorrect.\n\noutput: False",
      "Pembrolizumab is not well-studied in infants. Current pediatric recommendations are weight-based (≈2 mg/kg every 3 weeks, maximum 200 mg). A fixed 200 mg dose in a 2-month-old infant (likely <10 kg) far exceeds the recommended weight-based dose and raises significant safety concerns. Therefore, the statement is incorrect.\n\noutput: False",
      "Pembrolizumab’s approved flat dose of 200 mg every 3 weeks is intended for adults.  \nPediatric studies (generally ≥12 kg and ≥6 months of age) have used 2 mg/kg up to a maximum of 200 mg; there is essentially no safety-efficacy data in neonates or very young infants.  \nA 2-month-old infant weighs roughly 4-6 kg; giving a full 200 mg dose would deliver >30-40 mg/kg—an order of magnitude higher than weight-based pediatric dosing, and far beyond what has been studied.  \nTherefore, the statement that this dosage is appropriate for infants and poses no safety concerns is incorrect.  \n\noutput: False",
      "Pembrolizumab has very limited data in patients < 12 years old and none in 2-month-old infants.  \nWhen it is used in older pediatric populations, the recommended dose is weight-based at 2 mg/kg (maximum 200 mg) every 3 weeks. A 2-month-old infant typically weighs ≈4-6 kg, so the adult fixed dose of 200 mg would be roughly 30-50 mg/kg—far exceeding the pediatric recommendation.  \nSafety and efficacy in this age group are not established, and such a high relative dose carries significant risk. Therefore, the statement that this dosage “is appropriate for infants and does not pose safety concerns” is incorrect.\n\noutput: False",
      "Pembrolizumab pediatric dosing (outside of specific clinical trials) is weight-based at 2 mg/kg up to a maximum of 200 mg every 3 weeks. A 2-month-old infant typically weighs about 4–6 kg; the corresponding dose would therefore be roughly 8–12 mg, not 200 mg. Safety and efficacy data for immune-checkpoint inhibitors in infants are extremely limited, and administering a full adult flat dose poses significant risk for toxicity. Therefore, asserting that the 200 mg every-3-week regimen is appropriate and without safety concerns in this age group is not supported by established medical knowledge.\n\noutput: False",
      "Pembrolizumab has not been adequately studied in infants; its FDA-approved pediatric use begins at 12 years of age and is weight-based (2 mg/kg, maximum 200 mg). A flat 200 mg dose for a 2-month-old would far exceed the recommended weight-based amount and raises significant safety concerns. Therefore, the statement is incorrect.  \n\noutput: False",
      "Pembrolizumab has very limited data in pediatric patients and is not approved for use in infants as young as 2 months. When it is used in older children, the recommended dosage is weight-based (typically 2 mg/kg up to a maximum of 200 mg); a fixed adult dose of 200 mg every 3 weeks would far exceed an infant’s weight-based dose and could pose significant safety risks. Therefore, the statement that this dosage is appropriate and without safety concerns is incorrect.  \n\noutput: False",
      "Pembrolizumab has been very little studied in infants.  \nWhen used in children, the recommended regimen is 2 mg/kg (to a maximum of 200 mg) every 3 weeks.  \nA typical 2-month-old weighs roughly 4–6 kg, so the weight-based dose would be only about 8–12 mg.  \nAdministering the full adult flat dose of 200 mg therefore exceeds the pediatric weight-based dose by more than ten-fold, and its safety in this age group is unknown.  \nConsequently, the dose in the premise is not considered appropriate and does raise safety concerns.\n\noutput: False",
      "The fixed adult dose of pembrolizumab (200 mg IV every 3 weeks) has been studied and approved only for adults and, in weight-based form (2 mg/kg), for certain older pediatric patients. There are no data supporting its safety or appropriateness in a 2-month-old infant, and administering a full 200 mg dose would vastly exceed any weight-based recommendation, raising significant safety concerns. Therefore, the statement is incorrect.  \noutput: False",
      "Pembrolizumab dosing in children is generally weight-based (2 mg/kg every 3 weeks) and its safety and efficacy have not been established in infants. A fixed adult dose of 200 mg for a 2-month-old (≈5 kg) would be roughly 40 mg/kg—far above the recommended pediatric dose—and carries significant safety concerns. Therefore, the statement is incorrect.  \noutput: False"
    ]
  },
  "8": {
    "premise": "59-year-old male with relapsed acute lymphoblastic leukemia receiving methotrexate 250mg/m² intravenously daily for 10 consecutive days.",
    "statement": "This methotrexate regimen is well tolerated and does not significantly increase the risk of cumulative toxicity.",
    "label": false,
    "responses": [
      "The described regimen of methotrexate (250 mg/m² IV daily for 10 consecutive days, totaling 2,500 mg/m²) is considered a high-dose, intensive schedule that is well known to carry substantial risks of myelosuppression, mucositis, hepatotoxicity, nephrotoxicity, and other cumulative toxicities, especially in an older adult with relapsed acute lymphoblastic leukemia. Therefore, it cannot be characterized as “well tolerated” or as not significantly increasing cumulative toxicity.\n\noutput: False",
      "High-dose or prolonged methotrexate therapy (such as 250 mg/m² IV given daily for 10 days, totaling 2 500 mg/m²) is well known to cause significant cumulative toxicity—myelosuppression, mucositis, hepatotoxicity, nephrotoxicity, and neurotoxicity—especially in older adults. Therefore, the claim that this regimen is “well tolerated” and “does not significantly increase the risk of cumulative toxicity” is not supported by medical evidence.\n\noutput: False",
      "High‐dose or prolonged courses of methotrexate are well known to cause significant cumulative toxicity, including severe myelosuppression, mucositis, hepatotoxicity, and nephrotoxicity, especially in older adults. Administering 250 mg/m² intravenously every day for 10 consecutive days (total 2.5 g/m²) is an intensive regimen where cumulative toxicity is a major concern and close monitoring with leucovorin rescue and supportive care is typically required. Therefore, it is incorrect to claim that this regimen is “well tolerated” and does not significantly increase toxicity risk. \n\noutput: False",
      "Methotrexate at 250 mg/m² given intravenously every day for 10 consecutive days delivers a cumulative dose of 2.5 g/m². This represents a high-dose, multi-day regimen that is well known to carry substantial risks of cumulative toxicity—including myelosuppression, mucositis, hepatotoxicity, nephrotoxicity, and pulmonary toxicity—and therefore is not generally described as “well tolerated” or free of significant cumulative-toxicity concerns. \n\noutput: False",
      "Methotrexate 250 mg/m² given intravenously each day for 10 consecutive days represents a relatively high cumulative dose. Repeated daily doses of methotrexate are well-known to increase the risk of myelosuppression, mucositis, hepatotoxicity, nephrotoxicity, and other cumulative toxicities, especially in older adults and in the setting of relapsed leukemia. Therefore the claim that this regimen “is well tolerated and does not significantly increase the risk of cumulative toxicity” is not supported by established medical knowledge.\n\noutput: False",
      "The described regimen involves high‐dose, repetitive daily administration of methotrexate (total 2,500 mg/m² over 10 days), which is known to carry substantial risks of cumulative toxicity (e.g., myelosuppression, mucositis, hepatotoxicity, nephrotoxicity) and is not typically characterized as “well tolerated.” Therefore, the statement is not factually correct. \n\noutput: False",
      "High-dose or prolonged methotrexate schedules such as 250 mg/m² IV daily for 10 consecutive days are associated with substantial risks of myelosuppression, mucositis, nephrotoxicity, hepatotoxicity and other cumulative adverse effects, especially in a 59-year-old patient with relapsed ALL. Describing this regimen as “well tolerated” and as not significantly increasing cumulative toxicity is inconsistent with established pharmacologic and clinical experience.\n\noutput: False",
      "Clinical practice and published data show that giving methotrexate 250 mg/m² intravenously every day for 10 consecutive days is a very intensive schedule that carries a high risk of cumulative toxicity (myelosuppression, mucositis, hepatotoxicity, nephrotoxicity, etc.). Such a regimen is not generally described as “well-tolerated,” and the risk of cumulative toxicity is significant. Therefore the statement is not factually correct. \n\noutput: False",
      "Methotrexate 250 mg/m² given intravenously every day for 10 consecutive days is a very intensive, high-cumulative-dose regimen. Established pharmacology and clinical experience show that repeated high-dose methotrexate markedly increases the risks of myelosuppression, mucositis, hepatotoxicity, nephrotoxicity, and other adverse effects, particularly in older adults and in the setting of relapsed leukemia. Therefore it cannot be characterized as “well tolerated” or as posing no significant increase in cumulative toxicity risk.  \n\noutput: False",
      "Methotrexate at 250 mg/m² given intravenously every day for 10 consecutive days delivers a very large cumulative dose (≈2,500 mg/m²). Prolonged high‐dose methotrexate therapy is well known to increase the risks of severe myelosuppression, mucositis, hepatotoxicity, nephrotoxicity, and other cumulative toxicities, and therefore typically requires leucovorin rescue, hydration, and close monitoring. It cannot be characterized as uniformly “well tolerated” or as posing no significant additional risk of cumulative toxicity.\n\noutput: False"
    ]
  },
  "9": {
    "premise": "64-year-old patient with advanced pancreatic cancer receiving gemcitabine 1250mg/m² intravenously on Days 1–5 every 21 days for four cycles.",
    "statement": "This gemcitabine schedule is appropriate and does not pose excess risk of hematologic or liver toxicity.",
    "label": false,
    "responses": [
      "Gemcitabine is usually given for pancreatic cancer as  \n• 1000 mg/m² weekly for 7 weeks then one-week rest, followed by 1000 mg/m² on days 1, 8, 15 every 28 days, or  \n• 1000–1250 mg/m² on days 1 and 8 of a 21-day cycle.  \n\nAdministering 1250 mg/m² on five consecutive days (days 1–5) every 21 days doubles the usual cumulative dose for a cycle and is not an accepted schedule. Such dose-intensity markedly increases the risk of severe neutropenia, thrombocytopenia and transaminase elevation. Therefore, the statement claiming this schedule “does not pose excess risk of hematologic or liver toxicity” is not correct.\n\noutput: False",
      "Gemcitabine is usually given for pancreatic cancer at 1000 mg/m² once weekly for 7 of 8 weeks, or 1000–1250 mg/m² on Days 1 and 8 every 21 days.  \nAdministering 1250 mg/m² daily for 5 consecutive days every 21 days more than doubles the usual cumulative dose, markedly increasing the likelihood of severe neutropenia, thrombocytopenia, and transaminase/bilirubin elevations.  \nTherefore, the described schedule is not standard and is associated with excess hematologic and liver toxicity risk.  \n\noutput: False",
      "Gemcitabine is usually given for pancreatic cancer as 1000 mg/m² once weekly for 7 of 8 weeks, or 1000 mg/m² on Days 1, 8, 15 of a 28-day cycle, or 1000–1250 mg/m² on Days 1 and 8 every 21 days.  \nThe schedule in the premise—1250 mg/m² on five consecutive days every 21 days—delivers more than double the usual per-cycle dose, greatly increasing the risk of dose-limiting hematologic toxicity (neutropenia, thrombocytopenia, anemia) and hepatotoxicity (elevated transaminases, bilirubin).  \nTherefore, saying it “does not pose excess risk” and is “appropriate” is incorrect.\n\noutput: False",
      "The schedule described (gemcitabine 1250 mg/m² IV on Days 1–5 every 21 days) greatly exceeds the dose intensity of all commonly accepted regimens for pancreatic cancer and is associated with a markedly higher risk of severe myelosuppression and liver enzyme elevations. Therefore, the statement that it “does not pose excess risk of hematologic or liver toxicity” is not correct. \n\noutput: False",
      "Gemcitabine is usually administered for pancreatic cancer at 1000 mg/m² once weekly for 7 of 8 weeks, or 1000 mg/m² on Days 1, 8 and 15 of a 28-day cycle, or 1250 mg/m² on Days 1 and 8 of a 21-day cycle.  \nGiving 1250 mg/m² IV on five consecutive days every 21 days delivers more than double the usual cycle dose and greatly exceeds standard, evidence-based schedules. Such an intensive regimen is associated with a markedly higher incidence of dose-limiting neutropenia, thrombocytopenia and liver enzyme elevations. Therefore, saying that it “does not pose excess risk of hematologic or liver toxicity” is incorrect.\n\noutput: False",
      "Gemcitabine is usually given for pancreatic cancer at 1000 mg/m² once weekly for 7 weeks then 1-week rest, or 1000–1250 mg/m² on Days 1 and 8 of a 21-day cycle, or 1000 mg/m² on Days 1, 8, 15 of a 28-day cycle.  \nAdministering 1250 mg/m² on five consecutive days (total 6250 mg/m²) every 21 days far exceeds the cumulative dose and intensity of standard regimens. Such an intense schedule carries a markedly higher risk of severe myelosuppression (neutropenia, thrombocytopenia, anemia) and potential hepatotoxicity. Therefore, the schedule described is not considered appropriate and does pose excess risk of hematologic and liver toxicity.  \n\noutput: False",
      "Gemcitabine is ordinarily given for pancreatic cancer at 1000 mg/m² weekly for 3 of every 4 weeks, or similar schedules such as 1000–1250 mg/m² on days 1, 8 and 15 every 28 days.  \nAdministering 1250 mg/m² on five consecutive days (total 6250 mg/m² per 21-day cycle) greatly exceeds accepted cumulative dosing and is associated in studies with marked myelosuppression and potential hepatotoxicity. Therefore the described schedule is not considered appropriate and it does carry an excess risk of hematologic and liver toxicity.\n\noutput: False",
      "Gemcitabine’s accepted regimens for advanced pancreatic cancer are:\n• 1000 mg/m² IV over 30 min once weekly for 7 weeks followed by 1 week rest, then weekly for 3 weeks every 4 weeks, or  \n• 1000 mg/m² IV weekly ×3 every 28 days, or  \n• 1250 mg/m² IV on Days 1 and 8 of a 21-day cycle.\n\nGiving 1250 mg/m² on 5 consecutive days (total 6250 mg/m² over one week) has not been validated, markedly exceeds the usual per-cycle dose-intensity, and is known to produce substantially higher rates of grade 3-4 neutropenia, thrombocytopenia and transaminase elevation. Therefore this schedule is neither standard nor free of excess hematologic or hepatic risk.\n\noutput: False",
      "Gemcitabine monotherapy for advanced pancreatic cancer is typically given at 1000 mg/m² IV on days 1, 8 and 15 of a 28-day cycle (or similar reduced-frequency schedules).  \nAdministering 1250 mg/m² IV on five consecutive days every 21 days more than doubles the usual cumulative dose per cycle and exposes the patient to continuous myelosuppressive pressure without the customary recovery period. Published dose-finding studies identify neutropenia, thrombocytopenia and transaminase elevations as the dose-limiting toxicities when infusion frequency or total dose is intensified; a daily-for-5-days schedule at 1250 mg/m² is not an accepted standard regimen precisely because of excessive hematologic and hepatic toxicity.\n\nTherefore, the claim that this schedule is “appropriate and does not pose excess risk of hematologic or liver toxicity” is not supported by established evidence.\n\noutput: False",
      "Gemcitabine is usually given for pancreatic cancer at 1000 mg/m² once weekly for 7 weeks followed by a week off, and then once weekly on Days 1, 8, 15 of each 28-day cycle (or 1000 mg/m² on Days 1 and 8 of a 21-day cycle).  \nThe regimen in the premise (1250 mg/m² daily on Days 1–5 every 21 days) delivers more than double the approved cumulative dose per cycle (6250 mg/m² vs 3000 mg/m² in the standard schedule). Such a high-intensity schedule is not standard and is well-known to markedly increase the risk of severe myelosuppression and hepatotoxicity. Therefore, the statement that this schedule is “appropriate and does not pose excess risk of hematologic or liver toxicity” is incorrect.\n\noutput: False"
    ]
  },
  "10": {
    "premise": "60-year-old male with head and neck squamous cell carcinoma receiving cisplatin 250mg/m² daily for 7 consecutive days along with standard radiation therapy.",
    "statement": "This cisplatin dose is within safe limits and is not likely to cause kidney failure or ototoxicity.",
    "label": false,
    "responses": [
      "Cisplatin 250 mg/m² daily for 7 days (total 1750 mg/m²) is far above standard dosing for head and neck cancer (typically 100 mg/m² every 3 weeks or ~40 mg/m² weekly). Such an excessive cumulative dose carries a very high risk of nephrotoxicity and ototoxicity. Therefore, the statement that the dose is within safe limits and not likely to cause these toxicities is incorrect.  \n\noutput: False",
      "output: False",
      "Cisplatin doses used concurrently with head-and-neck radiotherapy are typically either 100 mg/m² once every 3 weeks (total three doses) or 30–50 mg/m² once weekly. Daily dosing at 250 mg/m² for 7 days (total 1,750 mg/m² in a week) far exceeds established safe limits and carries an extremely high risk of nephrotoxicity (kidney failure) and ototoxicity. Therefore, the statement is incorrect.  \noutput: False",
      "Standard concurrent chemoradiation regimens for head and neck cancer use either 100 mg/m² once every 3 weeks or 30–40 mg/m² weekly. A dose of 250 mg/m² per day for 7 consecutive days (total 1 750 mg/m² in one cycle) is many-fold higher than any recommended regimen and would carry an extremely high risk of serious cisplatin toxicities, including acute kidney injury and ototoxicity. Therefore, the statement that this dose is within safe limits and unlikely to cause these toxicities is incorrect.\n\noutput: False",
      "Cisplatin is usually given for head and neck chemoradiation as 100 mg/m² every 3 weeks (three cycles) or about 40 mg/m² once weekly.  \nA daily dose of 250 mg/m² for seven consecutive days would yield a cumulative dose of 1 750 mg/m², far exceeding recommended limits. Such exposure would carry an extreme risk of dose-limiting toxicities, especially nephrotoxicity (acute kidney injury) and ototoxicity (sensorineural hearing loss). Therefore the statement that this dose is “within safe limits” and “not likely” to cause kidney failure or ototoxicity is incorrect.\n\noutput: False",
      "The regimen described (250 mg/m² of cisplatin given daily for 7 days, totaling 1750 mg/m² in a week) vastly exceeds accepted dosing limits. Standard chemoradiation protocols for head and neck cancer typically use 100 mg/m² every 3 weeks or 30–40 mg/m² weekly, with cumulative doses above ~500–600 mg/m² known to markedly increase nephrotoxicity and ototoxicity risk. Therefore, the stated dose is not within safe limits and has a high likelihood of causing kidney failure and ototoxicity.\n\noutput: False",
      "Standard high-dose cisplatin regimens for head and neck cancer are 100 mg/m² every 3 weeks, or weekly doses of 30–40 mg/m². Nephrotoxicity and ototoxicity become much more likely when cumulative doses exceed ~400–500 mg/m².\n\nA regimen of 250 mg/m² per day for 7 days results in 1 750 mg/m² in one week—more than triple the usual cumulative threshold and far in excess of accepted single-dose limits. Such a dose is well outside safe limits and carries a very high risk of severe kidney injury and hearing loss.\n\noutput: False",
      "The prescribed cisplatin regimen (250 mg/m² daily × 7 days = 1750 mg/m² in one week) vastly exceeds standard dosing (e.g., 100 mg/m² every 3 weeks or 40 mg/m² weekly for concurrent chemoradiation). Such an excessive cumulative dose carries a very high risk of dose-limiting toxicities, notably nephrotoxicity leading to kidney failure and ototoxicity. Therefore, the statement that the dose is within safe limits and unlikely to cause these toxicities is incorrect.  \n\noutput: False",
      "Cisplatin doses used concurrently with radiation in head and neck cancer are usually 100 mg/m² every 3 weeks or about 40 mg/m² weekly. Even the high-dose regimens used in other settings seldom exceed a total of 100–120 mg/m² per cycle.  \nA dose of 250 mg/m² given daily for 7 days (total 1 750 mg/m²) is far beyond established safe limits. Such an excessive cumulative dose carries an extremely high risk of severe nephrotoxicity (acute kidney injury/renal failure) and ototoxicity, among many other toxicities.\n\nTherefore, the statement that this dose is within safe limits and unlikely to cause kidney failure or ototoxicity is factually incorrect.\n\noutput: False",
      "Typical cisplatin regimens for head-and-neck chemoradiation are 100 mg/m² once every 3 weeks or about 40 mg/m² once weekly. A daily dose of 250 mg/m² for 7 consecutive days (total 1 750 mg/m²) is far above accepted limits and would almost certainly lead to severe nephrotoxicity and ototoxicity. Therefore, the statement that this dose is within safe limits and unlikely to cause kidney failure or ototoxicity is incorrect.  \n\noutput: False"
    ]
  }
}